A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1600-1609

  Kohn, Elise C ^a,b   Reed, Eddie ^a   Sarosy, Gisele A ^a   Minasian, Lori ^a   Bauer, Kenneth S ^a   Bostick Bruton, Frieda ^a   Kulpa, Vyta ^b   Fuse, Eichi ^a   Tompkins, Anne ^a   Noone, Marianne ^a   Goldspiel, Barry ^d   Pluda, James ^c   Figg, William D ^a   Liotta, Lance A ^b  

^a Vascular Medicine Branch   (United States)

^b Laboratory of Pathology   (United States)

^c Cancer Therapy and Evaluation Program   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 0034901273     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. L651582, a novel antiproliferative and antimetastasis agent
2. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates
3. Structure function analysis of signal and growth inhibition by carboxyamido-triazole, CAI
4. Calcium influx modulates expression of matrix metalloproteinase-2 (72 kDa type IV collagenase, gelatinase A) expression
5. Angiogenesis: Role of calcium-mediated signal transduction
6. 2+ influx
7. Regulation of the Rho-A pathway in human endothelial cell spreading on type IV collagen: Role of calcium influx
8. Calcium-mediated signal transduction: Biology, biochemistry, and therapy
9. Thapsigargin-induced gene expression in nonexcitable cells is dependent on calcium influx
10. The role of calcium in the regulation of invasion and angiogenesis
11. Excitement about calcium signaling in inexcitable cells
12. Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI): Computer assisted analysis
13. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
14. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers
15. Phase I trial of micronized formulation CAI: Pharmacokinetics, clinical outcome, and comparison of formulations
16. Carboxyamido-triazole induces apoptosis in bovine aortic endothelial and human glioma cells
17. Molecular insights into cancer invasion: Strategies for prevention and intervention
18. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma
19. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma
20. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
21. Taxol induced polymerization of purified tubulin
22. Promotion of microtubule assembly in vitro by Taxol
23. Paclitaxel (Taxol)
24. The microtubule-affecting drug paclitaxel has antiangiogenic activity
25. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol
26. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
27. Dose intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
28. In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells
29. An optimized method for the quantitation of carboxyamido-triazole (CA1) in human plasma with solid phase extraction and reversed phase HPLC
30. Pharmacokinetics of orally administered carboxyamido-triazole (CAI), an inhibitor of calcium-mediated signal transduction
31. The pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters
32. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
33. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol
34. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer
35. Development of angiogenesis inhibitors for cancer therapy
36. Inhibitors of intracellular chloride regulation induce cisplatin resistance in canine osteosarcoma cells
37. Efficacy of addition of dose intense paclitaxel to cisplatin and cyclophosphamide for patients with newly diagnosed, advanced stage epithelial ovarian cancer
38. Paclitaxel-induced neuropathy
39. Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin
40. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
41. Chemotherapy for ovarian cancer: Current concepts
42. Single-agent paclitaxel and paclitaxel/nonplatinum combination therapy in advanced non-small cell lung cancer
43. A phase II study of Taxol in patients with malignant melanoma
44. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
45. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy
46. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1, 000 patients registered to National Cancer Institute Treatment Referral Center 9103
47. Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo
48. Identification and characterization of human metabolites of CAI [5-amino-1-1 (4′-chlorobenzoyl-3, 4-dichlorobenzyl)-1, 2, 3-triazole-4-carboxamide]
49. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
50. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
51. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
52. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
53. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound